Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

(2017) Venkat Reddy et al.   RHEUMATOLOGY

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus

(2016) Theofanis Karageorgas et al.   RHEUMATOLOGY

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

(2015) Kenneth C Kalunian et al.   ANNALS OF THE RHEUMATIC DISEASES

Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide

(2015) Christophe Macri et al.   Autophagy

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus

(2015) A Tocoian et al.   LUPUS

Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells

(2014) N. Rieth et al.   IMMUNOLOGY LETTERS

Ofatumumab: a novel treatment for severe systemic lupus erythematosus

(2014) C. C. Thornton et al.   RHEUMATOLOGY

Interferon-α Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers

(2013) Gareth A. D. Hardy et al.   PLoS One

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

(2012) Robert Zimmer et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

(2012) Jacqueline M. McBride et al.   ARTHRITIS AND RHEUMATISM

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

(2012) Bernard R. Lauwerys et al.   ARTHRITIS AND RHEUMATISM

Global Trend of Survival and Damage of Systemic Lupus Erythematosus: Meta-Analysis and Meta-Regression of Observational Studies from the 1950s to 2000s

(2012) Anselm Mak et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

Assessment of a lupus nephritis cohort over a 30-year period

(2011) S. C. Croca et al.   RHEUMATOLOGY

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial

(2008) Sylviane Muller et al.   ARTHRITIS AND RHEUMATISM